Last reviewed · How we verify
Ulcerative Colitis
Approved treatments
- Stelara · Biocon Biologics UK Ltd
- In open-label phase: treatment with tofacitinib · Pfizer
- tumor necrosis factor inhibitors (TNFi) · Pfizer
- Colazal · Valeant Pharms Intl
Colazal works by reducing inflammation in the gut by modulating the immune response. - Zeposia · Bristol-Myers Squibb
Zeposia works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression. - Carogra · EA Pharma Co., Ltd.
- Ovidrel · Merck KGaA
- Imuran · Legacy Pharma
- Entyvio · Takeda
Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue. - Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Cortone
- Sulfadiazine · Eli Lilly
- Rowasa · Meda Pharms
Rowasa works by blocking the production of prostaglandins, which are chemicals that cause inflammation in the rectum and colon. - Tasocitinib · Pfizer
- Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - TNF Inhibitor · Pfizer
- Stelara · Johnson & Johnson
Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation. - Remicade · Johnson & Johnson
Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses. - Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
- Azulfidine En-Tabs · Pfizer
- Remicade · Johnson & Johnson
Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding. - CYLTEZO · BOEHRINGER INGELHEIM
- IXIFI · PFIZER INC
- MESA · Meda Pharms
- Cortef · Generic (originally Merck/Upjohn)
- Xeljanz · Pfizer
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs. - Azulfidine En-Tabs · Pfizer
Anti-inflammatory and immunomodulatory properties with affinity for connective tissue and high concentration in serous fluids. - Simponi · Centocor Ortho Biotech Inc
Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation. - Jyseleca · Gilead Sciences Ireland UC
- Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - Remicade · Johnson & Johnson
Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage. - Xeljanz · Pfizer
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation. - Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- Simponi · Alvotech Swiss AG
- prednisolon · Hannover Medical School
- Humira · Sohag University
- Ovidrel · Nanjing University
- Ovitrelle · Hadassah Medical Organization
- TOFA
Clinical guidelines
- FDA label — 1L|adj
Sulfasalazine is indicated for the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis. - FDA label — 2L
XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. - FDA label — 1L|2L
Treatment of moderately to severely active ulcerative colitis in adult patients. - FDA label — 2L
reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. - FDA label — 1L|2L
Treatment of moderately to severely active ulcerative colitis in adult patients. - FDA label — 2L
XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: